Transcatheter Cardiovascular Therapeutics (TCT) 2009: Conference Review and Analysis

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Transcatheter Cardiovascular Therapeutics (TCT) 2009 – Conference Review and Analysis 6
2.1 Summary 6
2.2 Key Takeaways of TCT 2009 7
2.2.1 Drug Eluting Stents (DES) Pipeline 7
2.2.2 The Hybrid Cath Lab Operating Rooms (ORs) 7
2.2.3 Emerging Role of Genetics in Predicting Risk of Disease 7
3 TCT 2009 - Interventional Cardiology Outlook 8
3.1 Market Profile 8
3.2 Competitive Landscape 9
3.3 Key Companies at TCT 2009 10
3.3.1 Boston Scientific Corporation 10
3.3.2 Abbott Vascular 11
3.3.3 Medtronic Inc 14
3.3.4 Cordis Corp. 15
3.3.5 Spectranetics 15
3.3.6 Cardiva Medical Inc 16
4 TCT 2009 - Peripheral Vascular Devices Outlook 17
4.1 Market Overview 17
4.2 Competitive Landscape 18
4.3 Key Companies at TCT 2009 19
4.3.1 Pathway Medical Technologies 19
4.3.2 Cook Medical Incorporated 19
4.3.3 Minnow Medical, Inc 20
4.3.4 Abbott Vascular 21
4.3.5 Terumo Corporation 21
4.3.6 Vascular Solutions Inc 22
5 TCT 2009 - Prosthetic Heart Valves Outlook 23
5.1 Market Overview 23
5.2 Key Companies at TCT 2009 24
5.2.1 Coherex Medical Inc 24
5.2.2 Evalve Inc 25
5.2.3 Mardil Inc 26
6 TCT 2009 – Ventricular Assist Devices Outlook 27
6.1 Market Overview 27
6.2 Key Companies at TCT 2009 28
6.2.1 BIOMED Inc. 28
6.2.2 CardiacAssist Inc. 29
7 Other Companies at TCT 2009 30
7.1 Morris Innovative 30
7.1.1 Company Profile 30
7.1.2 Product Profile 30
7.1.3 Clinical Trial 30
7.2 ProSolv CardioVascular 31
7.2.1 Company Profile 31
7.2.2 Product Presented at TCT 2009 31
7.3 TeraRecon, Inc. 32
7.3.1 Company Profile 32
7.3.2 Product Presented at TCT 2009 32
7.4 Ardian Inc. 33
7.4.1 Company Profile 33
7.4.2 Product Presented at TCT 2009 33
7.4.3 Clinical Trial 33
7.5 PLC Systems Inc. 34
7.5.1 Company Profile 34
7.5.2 Product Presented at TCT 2009 34
7.5.3 Clinical Trial 34
7.6 Vascular Solutions 34
7.6.1 Company Profile 34
7.6.2 Product Presented at TCT 2009 34
8 Appendix 35
8.1 GlobalData Research Methodology 35
8.2 Secondary Research 36
8.3 Primary Research 37
8.4 Models 37
8.5 Forecasts 38
8.6 Expert Panel Validation 38
8.7 Currency Conversion 39
8.8 Contact Us 40
8.9 Disclaimer 40

1.1 List of Tables
Table 1: Interventional Cardiology, Global, Revenue ($m), 2000-2015 9
Table 2: TAXUS Express Horizon’s AMI Trial, Two Year Follow up Results 10
Table 3: XIENCE V (PROMUS) Spirit III Trial, Three Year Results 12
Table 4: XIENCE V (PROMUS) Spirit III Trial, in Diabetic Patients 12
Table 5: Peripheral Vascular Devices, Global, Revenue ($m), 2000-2015 18
Table 6: Prosthetic Heart Valve, Global, Revenue ($m), 2000-2015 24
Table 7: Ventricular Assist Devices, Global, Revenue ($m), 2000-2015 28
Table 8: FISH closure device Clinical Trial Details 31
Table 9: USD to Local Currency, Average Exchange Rate 2008 39

1.2 List of Figures
Figure 1: Interventional Cardiology, Global, Revenue ($m), 2000-2015 8
Figure 2: Interventional Cardiology, Company Shares, 2009 9
Figure 3: Peripheral Vascular Devices, Global, Revenue ($m), 2000-2015 17
Figure 4: Peripheral Vascular Device, Company Shares, 2009 18
Figure 5: Prosthetic Heart Valve, Global, Revenue ($m), 2000-2015 23
Figure 6: Ventricular Assist Devices, Global, Revenue ($m), 2000-2015 27
Figure 7: GlobalData Methodology 36